2. Search Result
Search Result
Results for "

Intestinal bowel disease

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

1

Biochemical Assay Reagents

3

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17623
    Tegoprazan
    2 Publications Verification

    CJ-12420; RQ-00000004

    		 Proton Pump Potassium Channel Na+/K+ ATPase Inflammation/Immunology
    Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan
  • HY-123630
    Allura Red AC

    FD&C RED NO. 40; CI 16035

    		 Environmental Pollutants Fluorescent Dye 5-HT Receptor Interleukin Related Reactive Oxygen Species (ROS) IFNAR Inflammation/Immunology
    Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .
    Allura Red AC
  • HY-N0671
    Rhapontin
    2 Publications Verification

    Rhaponiticin

    		 Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin
  • HY-147105
    LRH-1 agonist-2

    		Orphan Nuclear Receptor Interleukin Related Inflammation/Immunology
    LRH-1 agonist-2 (Compound 6N) is a selective, full LRH-1 agonist with an EC50 of 15.7 nM. LRH-1 agonist-2 directly interacts with the Thr352 and His390 residues in the LRH-1 binding pocket, promotes allosteric signaling to the activation function surface (AFS), stabilizes the AFS and enhances coactivator recruitment. LRH-1 agonist-2 induces the anti-inflammatory cytokine IL-10, and reduces the pro-inflammatory cytokines IL-1β and TNFα. LRH-1 modulator-1 exerts anti-inflammatory effects in intestinal organoids. LRH-1 modulator-1 can be used in studies related to inflammatory bowel disease .
    LRH-1 agonist-2
  • HY-P2221
    Glepaglutide
    1 Publications Verification

    ZP1848

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide
  • HY-125740
    Malvidin-3-glucoside chloride

    Malvidin-3-O-glucoside chloride; Oenin chloride

    		 NF-κB TNF Receptor NO Synthase Interleukin Related Inflammation/Immunology
    Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health .
    Malvidin-3-glucoside chloride
  • HY-44809
    Izilendustat

    		HIF/HIF Prolyl-Hydroxylase Bacterial Cardiovascular Disease Infection Inflammation/Immunology
    Izilendustat is a potent prolyl hydroxylase inhibitor. Izilendustat competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia .
    Izilendustat
  • HY-70005
    CPA inhibitor
    3 Publications Verification

    Carboxypeptidase inhibitor

    		 Carboxypeptidase Wnt β-catenin Inflammation/Immunology
    CPA inhibitor (Compound 5) (Carboxypeptidase inhibitor) is an orally active competitive carboxypeptidase A (CPA) inhibitor with a Ki value of 0.32 μM. CPA inhibitor blocks the activity of carboxypeptidase A3 (CPA3). CPA activator activates the Wnt/Lrp6/β-catenin signaling pathway. CPA inhibitor reduces epithelial damage. CPA inhibitor is applicable to research related to inflammatory bowel disease, including ulcerative colitis and Crohn's disease .
    CPA inhibitor
  • HY-P2221B
    Glepaglutide acetate
    1 Publications Verification

    ZP1848 acetate

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide acetate
  • HY-W013636C
    2-Ketoglutaric acid potassium
    5+ Cited Publications

    Alpha-Ketoglutaric acid potassium

    		 Tyrosinase Endogenous Metabolite TNF Receptor Neurological Disease Metabolic Disease
    2-Ketoglutaric acid (Alpha-Ketoglutaric acid) (potassium) is an intermediate in the production of ATP or GTP in the Krebs cycle. 2-Ketoglutaric acid potassium is a reversible and orally active inhibitor of tyrosinase with an IC50 value of 15 mM. 2-Ketoglutaric acid potassium also acts as the major carbon skeleton for nitrogen-assimilatory reactions. 2-Ketoglutaric acid potassium significantly suppresses abnormal intestinal permeability, delocalization of tight junction proteins from the intestinal cells, expression of TNFα in vitro and in vivo. 2-Ketoglutaric acid potassium directly binds to TAK1, and inhibits the TRAF6-TAK1 interaction. 2-Ketoglutaric acid potassium also alleviates inflammatory bowel disease (IBD) symptoms and gut microbiota dysbiosis, evident by the improvements in the intestine length .
    2-Ketoglutaric acid potassium
  • HY-P2758
    Diamine oxidase

    DAO

    		 Biochemical Assay Reagents Metabolic Disease Inflammation/Immunology Cancer
    Diamine oxidase (DAO) is an orally active enzyme. Diamine oxidase catalyzes oxidative deamination of various polyamines. Diamine oxidase degrades histamine and polyamines to maintain the metabolic balance of amines in the body. Diamine oxidase is a key regulatory enzyme in rapidly proliferating tissues such as bone marrow and intestinal mucosa. Diamine oxidase can be used in research related to intestinal diseases, small bowel transplant rejection, histamine intolerance, and other conditions .
    Diamine oxidase
  • HY-107831
    5-Acetylsalicylic acid
    1 Publications Verification

    		 Drug Derivative Inflammation/Immunology Cancer
    5-Acetylsalicylic acid is the derivate of Aspirin (HY-14654), with anti-inflammatory property. 5-Acetylsalicylic acid is the active metabolite of Sulfasalazine (HY-14655) and its production is regulated by beneficial bacteria in the gut but is confined to the intestinal tract. 5-Acetylsalicylic acid exhibits a mild cytotoxicity effect on B16F10 cells. 5-Acetylsalicylic acid can be used for the study of inflammatory bowel disease (IBD) such as ulcerative colitis (UC) .
    5-Acetylsalicylic acid
  • HY-N0671R
    Rhapontin (Standard)
    2 Publications Verification

    Rhaponiticin (Standard)

    		 Reference Standards Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .
    Rhapontin (Standard)
  • HY-175310S
    Voderdeucitinib

    		JAK Inflammation/Immunology
    Voderdeucitinib (Compoudn I) is a TYK2 inhibitor with an anti-inflammatory activity. Voderdeucitinib can be used for inflammatory and autoimmune disease research, such as rheumatoid arthritis (RA), multiple sclerosis and intestinal bowel disease (IBD) .
    Voderdeucitinib
  • HY-17623S
    Tegoprazan-d6

    CJ-12420-d6; RQ-00000004-d6

    		 Proton Pump Na+/K+ ATPase Metabolic Disease
    Tegoprazan (CJ-12420; RQ-00000004), a potassium-competitive acid blocker, is a reversible, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H +/K +-ATPases in vitro. Tegoprazan significantly improves colitis in mice and enhances the intestinal epithelial barrier function. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
    Tegoprazan-d6
  • HY-125740R
    Malvidin-3-glucoside chloride (Standard)

    Malvidin-3-O-glucoside chloride (Standard); Oenin chloride (Standard)

    		 Reference Standards Interleukin Related NO Synthase NF-κB TNF Receptor Metabolic Disease Inflammation/Immunology
    Malvidin-3-glucoside (Malvidin-3-O-glucoside; Oenin) chloride (Standard) is the analytical standard of Malvidin-3-glucoside chloride (HY-125740). This product is intended for research and analytical applications. Malvidin-3-glucoside chloride is an orally active inhibitor of the NF-κB pathway, which blocks inflammatory responses induced by TNF-α, reduces IκB-α degradation and p65 nuclear translocation, and upregulates endothelial nitric oxide synthase eNOS to increase NO production. Malvidin-3-glucoside chloride exerts anti-inflammatory and antioxidant effects by inhibiting pro-inflammatory molecules such as MCP-1, ICAM-1, and IL-6, and regulating intestinal microorganisms and metabolites, while protecting endothelial cells and improving intestinal microecological dysbiosis under inflammatory conditions. Malvidin-3-glucoside chloride can be used to study chronic inflammatory-related diseases such as atherosclerosis and inflammatory bowel disease, and has the potential to prevent vascular inflammation and improve intestinal health .
    Malvidin-3-glucoside chloride (Standard)
  • HY-123630R
    Allura Red AC (Standard)

    FD&C RED NO. 40 (Standard); CI 16035 (Standard)

    		 Fluorescent Dye Interleukin Related 5-HT Receptor IFNAR Reactive Oxygen Species (ROS) Reference Standards Inflammation/Immunology
    Allura Red AC (Standard) is an analytical standard of Allura Red AC. This product is intended for research and analytical applications. Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety .
    Allura Red AC (Standard)
  • HY-127023
    Eicosapentaenoyl serotonin

    EPA-5-HT

    		 Endogenous Metabolite FAAH Interleukin Related Tyrosine Hydroxylase Metabolic Disease
    Eicosapentaenoyl serotonin (EPA-5-HT) is an endogenous fatty acid-serotonin conjugate lipid mediator. Eicosapentaenoyl serotonin acts as an inhibitor of fatty acid amide hydrolase (FAAH). Eicosapentaenoyl serotonin suppresses IL-17 release in Concanavalin A (HY-P2149)-stimulated human peripheral blood mononuclear cells. Eicosapentaenoyl serotonin is regulated by polyunsaturated fatty acids and modulates intestinal immunity and Th17 signaling. Eicosapentaenoyl serotonin can be used for the study of inflammatory bowel disease-related mechanisms .
    Eicosapentaenoyl serotonin
  • HY-P10842
    d-GLP-2 E33A

    		GLP Receptor Akt Metabolic Disease Inflammation/Immunology
    d-GLP-2 E33A is an agonist for the glucagon-like peptide 2 receptor (GLP-2R) with an EC50 of 414 nM. d-GLP-2 E33A can activate GLP-2R and increase the phosphorylation of AKT, but has no stimulative effect on GLP-1R. d-GLP-2 E33A can be used in the study of diseases such as intestinal malabsorption and inflammatory bowel diseases .
    d-GLP-2 E33A
  • HY-176554
    sEH-IN-21

    		Epoxide Hydrolase NF-κB Interleukin Related TNF Receptor Metabolic Disease Inflammation/Immunology
    sEH-IN-21 is an orally active sEH inhibitor with IC50s of 0.1 nM for hsEH and msEH. sEH-IN-21 potently inhibits NF-κB signaling pathways. sEH-IN-21 shows a strong anti-inflammatory activity, decreases the release of IL-6 and TNF-α and maintained the integrity of the intestinal barrier. sEH-IN-21 can be used for the study of inflammatory bowel disease (IBD) .
    sEH-IN-21
  • HY-44809A
    Izilendustat hydrochloride

    		HIF/HIF Prolyl-Hydroxylase Bacterial Cardiovascular Disease Infection Inflammation/Immunology
    Izilendustat hydrochloride is a potent prolyl hydroxylase inhibitor. Izilendustat hydrochloride competitively inhibits HIFPH2 activity, blocks HIF-1α degradation, stabilizes HIF-1α and HIF-2α proteins, and upregulates downstream target gene expression. Izilendustat hydrochloride can reduce intestinal inflammation and damage, enhance the ability of phagocytes to clear pathogens, and improve ischemia-related pathological phenotypes. Izilendustat hydrochloride can be used for the research of inflammatory bowel disease, ischemic vascular disease and anemia .
    Izilendustat hydrochloride
  • HY-171837A
    t9,t11,c15-CLNA

    		TNF Receptor Interleukin Related SOD Inflammation/Immunology
    t9,t11,c15-CLNA is a conjugated linolenic acid (CLNA) isomer produced by Lactobacillus plantarum ZS2058. t9,t11,c15-CLNA has the main activities of anti-inflammatory, antioxidant and improving intestinal barrier function. The regulatory mechanism of t9,t11,c15-CLNA includes upregulation of tight junction proteins, inhibition of pro-inflammatory cytokines (such as TNF-α, IL-6) and activation of antioxidant enzymes (such as SOD, CAT). t9,t11,c15-CLNA can be used in the study of inflammatory bowel diseases (such as colitis) .
    t9,t11,c15-CLNA
  • HY-183809
    ZSW

    		Hexokinase Inflammation/Immunology
    ZSW is a hexokinase 2 (HK2) inhibitor with human HK2 IC50 of 0.48 μM, human HK2 Ka of 252.00 μM, and selectivity over HK3 and GCK. ZSW binds directly to HK2, inhibits its enzymatic activity, modulates macrophage phenotypes through glycolysis inhibition, and inhibits NF-κB nuclear translocation by preventing IκBα phosphorylation and degradation. ZSW alleviates inflammatory bowel disease (IBD) and improves the intestinal inflammatory state of IBD mice. ZSW can be used for the research of inflammatory bowel disease .
    ZSW
  • HY-107831R
    5-Acetylsalicylic acid (Standard)

    		Reference Standards Others Inflammation/Immunology Cancer
    5-Acetylsalicylic acid (Standard) is the analytical standard of 5-Acetylsalicylic acid (HY-107831). This product is intended for research and analytical applications. 5-Acetylsalicylic acid is the derivate of Aspirin (HY-14654), with anti-inflammatory property. 5-Acetylsalicylic acid is the active metabolite of Sulfasalazine (HY-14655) and its production is regulated by beneficial bacteria in the gut but is confined to the intestinal tract. 5-Acetylsalicylic acid exhibits a mild cytotoxicity effect on B16F10 cells. 5-Acetylsalicylic acid can be used for the study of inflammatory bowel disease (IBD) such as ulcerative colitis (UC) .
    5-Acetylsalicylic acid (Standard)
  • HY-179379
    EP4 receptor agonist 3 prodrug

    		Drug Derivative Inflammation/Immunology
    EP4 receptor agonist 3 prodrug (Compound 9) is a prodrug of EP4 receptor agonist (Compound 1a). EP4 receptor agonist 3 prodrug itself has no agonistic activity on the EP4 receptor and needs to be specifically hydrolyzed by intestinal alkaline phosphatase (IAP) in the intestine to release the active molecule, which then exerts the EP4 receptor agonistic effect locally in the intestine. EP4 receptor agonist 3 prodrug has colonic targeting properties and significantly alleviates colitis in mice .
    EP4 receptor agonist 3 prodrug

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: